John Kao, MD
Interventional Cardiology · Honolulu, HINPI 1336187517
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Cardiovascular Systems Inc. at 47.8% of the total.
Across 43 payments — averaging $129.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$3K
- Philips North America LLC$723
- Penumbra, Inc.$564
- Boston Scientific$514
- Abbott$287
- Abiomed$257
- plus $557 from 6 others
Across 22 payments — averaging $1644.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$28K
- Abbott$8K
What the payments were for
- Speaking & faculty fees$2,52045%
- Travel & lodging$72313%
- Food & beverage$2,29841%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 4 | $2,659 |
| Philips North America LLC | 3 | $723 |
| Penumbra, Inc. | 3 | $564 |
| Boston Scientific | 14 | $514 |
| Abbott | 4 | $287 |
| Abiomed | 4 | $257 |
| Angiodynamics, Inc. | 1 | $179 |
| Shockwave Medical, Inc | 1 | $124 |
| Bayer | 4 | $109 |
| Medtronic | 3 | $99 |
| Teleflex LLC | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few interventional cardiology providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 222 | $336,226 |
| EntrestoSacubitril/Valsartan | 173 | $293,016 |
| JardianceEmpagliflozin | 92 | $129,835 |
| Repatha SureclickEvolocumab | 70 | $52,623 |
| BrilintaTicagrelor | 49 | $48,922 |
| XareltoRivaroxaban | 13 | $15,581 |
| VascepaIcosapent Ethyl | 13 | $11,303 |
| Atorvastatin Calcium | 350 | $11,047 |
| Metoprolol Succinate | 489 | $8,109 |
| Ranolazine ErRanolazine | 33 | $4,996 |
| ClopidogrelClopidogrel Bisulfate | 149 | $3,859 |
| Losartan Potassium | 229 | $3,657 |
| Ezetimibe | 63 | $2,991 |
| Amlodipine Besylate | 241 | $2,932 |
| Rosuvastatin Calcium | 66 | $2,720 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Honolulu
- John CoganHonolulu$82K
- Kris KawamotoHonolulu$25K
- Giselle Baquero CaranamaHonolulu$20K
- Atsushi TerakuboHonolulu$20K
- Kelly PaschkeHonolulu$7K
- John O'MaraHonolulu$5K
- Brandon KaiHonolulu$3K
- Jay GadgilHonolulu$2K
- Marie NguyenHonolulu$189
- Jason CallWailuku$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.